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Abstract
Generally, pain can be described as an unpleasant sensory or emotional 
 experience associated with tissue damage. Chronic pain has become a public health 
problem because among 35 and 75% of the world population has shown the symp-
tom. In particular, neuropathic pain has shown high comorbidity disorders such as 
anxiety and depression. Conventional therapies for treating pain include nonste-
roidal anti-inflammatory drugs (NSAIDs), corticosteroids, tricyclic antidepres-
sants, anticonvulsants, and opioids, which usually cause some side effects such as 
gastritis, headache, liver and kidney toxicity, and drug dependence. Conventional 
pharmaceuticals also tend to be expensive, and they cannot be easily afforded in 
developing countries, which have led to the use of natural products as an alternative 
treatment. In this chapter, we reviewed the current research of natural products 
for pain treatment. We also describe preclinical studies that assess the effect of 
some natural products on pain therapy, phytochemistry research, toxicity, adverse 
effects, and biosecurity. We also describe how conventional pain is managed and 
the possible use of compounds obtained from vegetable species for pain treatment.
Keywords: pain, analgesic, anti-inflammatory, herbal medicine, phytopharmaceuticals
1. Introduction
Over the course of history, the pain has been manifested in a wide range of forms, 
and it has not been treated properly. It is estimated that approximately 116 million 
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Kind of drug Type of pain Examples Doses Side effect
NSAIDs Nociceptive Acetaminophen 325–1000 mg PO every 4–6 h; max dose 4 g per day GI irritation, renal, and hepatic dysfunction
Diclofenac 50 mg PO every 8 h; max dose 150 mg per day GI irritation, bleeding, hepatic, and renal dysfunction
Ibuprofen 200–400 mg PO every 6 h; 1.2 g per day GI irritation, bronchospasm, bleeding, and renal dysfunction
Naproxen 250 mg PO every 6–8 h; max dose 1 g per day GI irritation, bleeding, renal dysfunction, and bronchospasm
Indomethacin 25 mg PO every 8–12 h; max dose 100 mg per day GI irritation, renal, and hepatic dysfunction
Opiates Nociplastic/
neuropathic
Tramadol 25–50 mg PO every 6–8 h; max dose 400 mg per day Dizziness, drowsiness, nausea, dry mouth, vomiting, and 
constipation
Morphine 10–15 mg PO 3–6 h; 0.1 mg/kg IV Nausea, vomiting, drowsiness, constipation, and sedation
Oxycodone 5–10 mg PO every 3–6 h Constipation, nausea, vomiting, drowsiness, dry mouth, 
hallucinations, and delirium
Hydromorphone 2–4 mg PO; 0.25–0.5 mg/kg every 6 h Pruritus, nausea, and rapid sedation
Fentanyl 0.5 mcg/kg Blurred vision, nausea, confusion, dizziness, and irregular 
heartbeats
Anticonvulsants Nociplastic/
neuropathic
Gabapentin Stepwise increase every 3–5 days from 300 mg to 
1200 PO every 8 h; max dose 3.6 g per day
Fatigue, ataxia, nystagmus, weight gain, and dizziness
Pregabalin 50–75 mg PO every 12 h Dizziness, fatigue, weight gain, and thrombocytopenia
Phenytoin 100 mg PO every 12 h; max dose 200 mg per day Nausea, vomiting, constipation, dizziness, drowsiness, trouble 
sleeping, or nervousness
Antidepressants Neuropathic Amitriptyline Stepwise increase every 7–10 days from 25 mg to 50 
PO every 6 h; max dose 200 mg per day
Vomiting, nausea, diarrhea, mouth pain, unusual taste, weight 
gain, urinary retention, and rash
Venlafaxine Stepwise increase every day from 75–150 mg PO 
every 8 h; max dose 150 mg per day
Libido reduction, loss of appetite, nausea or vomiting, 
constipation, dry mouth, trouble sleeping, and lack of energy
Mirtazapine Stepwise increase every 2 weeks from 15 to 45 mg PO 
a day; max dose 45 mg per day
Dry mouth, drowsiness, constipation weight gain, weakness, lack 
of energy, and dizziness
3 P
h
arm
a
ceu
tica
l an
d
 B
otan
ica
l M
an
a
gem
en
t of P
ain
 A
ssocia
ted
 w
ith
 P
sych
op
a
th
ology…
D
O
I: h
tt
p
://d
x.d
oi.org/10.5772/in
tech
op
en
.91154
Kind of drug Type of pain Examples Doses Side effect
Others Neuropathic Ketamine 0.115–0.3 mg/kg IV Nausea or vomiting, agitation, dizziness, and a sensation of 
unreality
Propofol 30–40 mg IV repeating 10 mg every 3–5 min; max 
dose 120 mg per day
Hypotension, sedation, respiratory depression, and 
hypertriglyceridemia
Capsaicin Cream: 3–4 times per day; patches: one time a day 
and repeated as often as every 3 months
Burning, dryness, itching, redness, swelling, or soreness at the 
application site
PO, per os rout; IV, intravenous rout; GI, gastrointestinal.
Table 1. 
Drugs used in acute and chronic pain.
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Americans have experienced chronic pain, which is higher than those affected by 
chronic diseases, such as heart disease, cancer, and diabetes, among others. The sim-
plest way to classify pain is based on its intensity as mild, moderate, and severe or using 
a scale from 0 to 10, where 0 is the lowest and 10 the highest. Other scales that are 
typically used are the unimodal scale such as the Analog Verbal Scale (AVS), the Visual 
Analog Scale (VAS), and the Numerical Scale (NS), among others. These scales are 
somewhat informal because pain is not easy to measure. Therefore, variations might 
affect critical evaluation when pain is manifested in all forms. Some authors refer to the 
use of the one-dimensional test to reach a standardized measure of pain; however, the 
researcher must adjust the test depending on the type of pain and type of research.
Aspirin and morphine, which are derived from plants, have been widely used 
for analgesic purposes. These compounds belong to nonsteroidal anti-inflammatory 
(NSAIDs) and opiate drug groups, respectively, and they are the most used 
nowadays [1]. Once the pain evolves and becomes chronic, several types of oral 
neuromodulators are often included in the patient treatment, for example, certain 
anticonvulsants and antidepressants [2], see Table 1.
In 2012, the use of NSAIDs in North America represented 98 million of the total 
prescriptions, and more than 29 million adults were regular users of these medica-
tions. Furthermore, a study in Sweden showed that these types of medications were 
the most commonly prescribed oral analgesics for the musculoskeletal system, with 
79% of prescriptions for a period of 5 years [3]. Opioid consumption causes side 
effects such as physical dependence, tolerance, and addiction, while NSAIDs cause 
intestinal disorders and ulceration [4]. Because the long-term pain treatment with 
conventional medicine is expensive and people commonly know the side effects that 
these may cause, patients tend to look at alternative drugs, most of the times based 
on herbal treatments. However, patients do not inform the use of natural products 
to their physicians, which may lead to potential health problems caused by pharma-
cological interactions with other drugs prescribed. This represents a relevant issue 
in countries where the use of plants is common but not necessarily regulated [5]. In 
the search for new effective and safe alternatives to treat several processes of pain, 
natural resources have been a relevant option for current medicine. Considering that 
pain is one of the most persistent and disabling manifestations present in several 
diseases, it has been increasingly becoming a major health problem, and it is also a 
challenge for modern medicine. Therefore, it is necessary to fully understand the 
pathophysiology of pain as well as alternatives that might be effective for treating it.
2. Pain classification, semiology, and diagnosis
The International Association for the Study of Pain (IASP) defines pain as “an 
unpleasant sensory and emotional experience associated with actual or potential tis-
sue damage or described in terms of such damage” [6]. Each person reacts differently 
to a pain stimulus, even before similar situations and injuries. Since pain is learned 
and sensed from the early stages of life, how people describe is often related to a 
particular personal experience including a patient’s culture, traumatic experiences, 
mood, biological aspects, and genetics. The words “pain” and “suffering” have often 
been used as synonyms, but the experience of suffering has been differentiated from 
pain. Suffering has been defined not only as a complement to the pain experience but 
also as vulnerability, dehumanization, a lost sense of self, lack of control over time 
and space, and the inability to find a meaning or purpose of the painful experience. 
The term “suffering” conveys the experience of pain beyond sensory attributes [7].
There are several ways to classify pain. The most common classification considers 
aspects such as origin, duration, neurophysiological characteristics, and intensity. 
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Based on its origin, pain could be oncological and nononcological. Oncological pain 
is caused by a cancerous process (invasion, understanding, infiltration, obstruction, 
etc.), associated with therapy (chemotherapy, radiotherapy, etc.), acute pain caused 
by diagnostic procedures (lumbar puncture, pleurodesis, embolization, opioid-
induced hyperalgesia, etc.), and that is associated with neoplastic or related pathol-
ogy (vertebral collapse, intratumoral hemorrhage, myalgia associated with sepsis, 
etc.) [8]. Noncancer pain is classified based on its duration as acute and chronic. 
The first one is limited to the time duration of fewer than 3 months. Noncancer 
pain has a little psychological component and usually affects somatic or visceral 
structures. By contrast, chronic pain has an unlimited duration, lasting more than 3 
months. Chronic pain differs from acute pain in the pathophysiological mechanisms 
and in its temporality in which the adaptive physiological process that character-
izes is shown [9–11]. In 2019, a new classification of chronic pain was proposed by 
the World Health Organization (ICD-11) [12], according to its neurophysiological 
characteristics, as nociceptive, neuropathic, and nociplastic [6, 12], see Table 2.
Recently, an international multidisciplinary research group proposed to the 
scientific community a fifth definition of pain called mixed pain, which is produced 
by a complex overlap of the different types of pain known (nociceptive, neuro-
pathic, and nociplastic) in any combination, acting simultaneously and/or concur-
rently to cause pain in the same area of the body, either acutely or chronic [13]. 
This difficulty of evaluating pain makes possible to resort to instruments that, with 
the minimum effort of the patient, are easily understandable, reliable, and valid. 
Type of pain Nociceptive Neuropathic Nociplastic
Origin Somatic Visceral Central nervous 
system
Neurophysiologic
Receptors Cutaneous or 
deep tissues such 
as skin, muscles, 
tendons, 
fascia, bones, 
or periosteum 
nociceptors
Walls of 
abdominal 
viscera 
nociceptors
Produced by 
dysfunction 
or injury to 
peripheral nerve 
pathways in 
the absence of 
demonstrable 
tissue damage
Peripheral receptors 
or injury of the 
somatosensory 
system
Characteristics Specific 
localization 
stabbing, acute, 
or chronic and 
shows periods 
of exacerbation 
with variable 
intensity 
depending on 
the inducing 
stimulus
Deep, 
spastic, and 
oppressive, 
poorly located 
or may be 
referred to 
as cutaneous 
surface distant 
from the 
origin of pain
Stabbing, 
burning, 
paroxysmal 
accompanied 
by paresthesia, 
dysesthesia, 
hyperalgesia, 
and allodynia, 
with a sensory 
deficit
Altered nociception 
even though there is 
no clear evidence of 
actual or potential 
tissue damage
Examples Burns, bumps, 
bruises, sprains, 
and bone 
fractures
Shoulder pain 
in myocardial 
infarction
Postherpetic 
neuralgia, 
carpal tunnel 
syndrome, 
peripheral 
neuropathy, and 
phantom limb 
pain
Fibromyalgia, 
chronic fatigue, 
vulvodynia, and 
interstitial cystitis
Table 2. 
Classification of the chronic pain according to the World Health Organization.
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These include the McGill Pain Questionnaire (MPQ ), Lattinen Test, Spanish Pain 
Questionnaire (CDE), Chronic Pain Coping Questionnaire (CAD), West Haven-
Yale Multidimensional Pain Inventory (WHYMPI), Brief Pain Inventory, and the 
scales of assessment of neuropathic pain: the LANSS Pain Scale, the Neuropathic 
Pain Questionnaire (NPQ ), Questionnaire DN4 (DN4), and Pain DETECT, among 
others [14]. It is important to note that the purpose of these tests is to assist the 
clinicians in assessing the severity of the pain or its causes. Tests correctly classify 
the patients as suffering from nociceptive and neuropathic pain.
3. Pain epidemiology
Epidemiological studies have shown that in the last month approximately half 
of people will have experienced an episode of pain that lasted at least 1 day, and the 
most common sites reported, in a study in the UK population, were the part lower 
back (30%), hip (25%), neck and shoulder (25%), and knee (24%) [15]. According 
to the US Institute of Medicine, 80% of patients who undergo surgery report 
postoperative pain, and 88% of these patients indicate moderate, severe, or extreme 
pain levels, if improperly managed between 10 and 60% of them will develop 
persistent pain postoperative [16].
Concerning to oncologic pain, a systemic review that covered the period from 
1966 to 2005 documented that the prevalence of pain after curative procedures of 
cancer pathology was 33% (95% CI 21–46%). While in those who were managed 
with anticancer therapy, pain occurred in 59% (CI 44–73%); in those with an 
advanced, terminal disease and with metastasis in 64% (CI 58–69%) and patients 
with any disease status in 53% (CI 43–63%). Of the patients with pain, more than 
a third presented moderate to severe intensity, with a high prevalence in patients 
with head and neck cancer (70%; 95% CI 51–88%) [8]. To chronic pain, the higher 
prevalence was unemployed, people without one university degree who live in 
poverty or rural areas. About the prevalence by sex and age, women and the elderly 
showed an elevation of this kind of pain [17].
Regarding the bad management of acute pain, there is a risk that a chronic painful 
syndrome will develop, with all its consequences for the patient, for his family and his 
environment. The chronicity of pain commonly involves anxiety, depression, fatigue, 
cognitive difficulty, and insomnia. Functional limitations and the consequent 
absence from work have been considered as part of the impact on the quality of life 
of high-impact diseases. It is currently known that people with chronic pain are more 
likely to have disabilities than those without pain. In addition, this disability is more 
likely in this condition than in any chronic health condition, including stroke, kidney 
failure, cancer, diabetes, and heart disease. The impact in terms of work absenteeism 
is evident both for the individual (loss of self-esteem, income, and low quality of life) 
and for the society (loss of productivity and higher health care expense) [18].
Pain is a major global public health problem because it has an important social 
and economic impact. It is necessary to have a clear understanding of the types of 
sensory signs and symptoms that should be assessed as pain since it is an individual 
and subjective experience.
4. Pain comorbidity
The pain usually accompanies various diseases, such as organ failure or mental dis-
order. A high number of patients with a mental disorder show some type of pain, but 
not all have any significant physical injury to justify such pain [19]. The relationship 
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between chronic pain and psychiatric disorders in addition to comorbidity is that 
these disorders may arise the risk of chronic pain, as well as the pain can contribute to 
developing psychiatric disorders. Among the most common diseases with which it is 
related are anxiety, depression, dementia, and schizophrenia [20].
Pathological anxiety is one of the most common mental disorders. It is an emo-
tion that is characterized by an exaggerated concern for future events or situations 
of uncertainty [21]. Anxiety disorder can affect the response of pain in various 
forms or states. A clinical study assayed on healthy female volunteers explored 
the effects of a particular type of anxiety (pain anxiety). The volunteer received 
electrocutaneous pain stimuli and the pain anxiety where measured by the Fear of 
Pain Questionnaire and Pain Anxiety Symptoms Scale. Three or six months later, 
the evaluated group was asked to rate the pain anxiety that they felt when the test 
was developed. It was demonstrated that pain anxiety can influence the memory of 
unpleasant experiences like experimental pain [22].
Anxiety is also common in diseases involving chronic pain stages such as mul-
tiple sclerosis and arthritis, in which anxiety disorder is more prevalent than in the 
general population. This psychiatric disorder also can contribute to the develop-
ment and severity of symptoms of inflammatory arthritis [23]. A study conducted 
in patients (58% female, mean age 43) who were receiving opioid agonist therapy 
for chronic pain showed that the weekly practice of hatha yoga for 3 months can 
reduce the level of pain and perhaps mediated by the decrease of emotional symp-
toms such as anxiety [24].
Neuroanatomical correlates to the response to anxiety are very complex, involv-
ing various structures such as the medial prefrontal cortex, hypothalamic and 
amygdaloidal nuclei, the hippocampal formation, and the gray matter of the central 
portion of the midbrain. Patients with some anxiety disorder show a common pat-
tern of activity of the hypothalamic-pituitary-adrenal (HPA) axis [21]. These areas 
are also related to the activation of the pain signaling pathway. On the other hand, 
when there is chronic pain, there is also hyperadrenalism and a decrease in the 
catecholaminergic pathway, as well as the activation of the HPA axis with continu-
ous release of corticosteroid hormones. These alterations are also present in the 
population with some anxiety disorder and are prior to the onset of pain, so when 
activated, it works as a modulator for the response and activation of pain [25].
Depression is another mental illness that has grown in incidence and prevalence 
in recent years. This disorder is responsible for more lost each year than any other 
disorder, and this is mainly because many people suffer from this (about 350 million 
people worldwide) [26]. Patients with this disorder experience different types of 
pain, such as chronic pain, fibromyalgia, rheumatoid arthritis, headache, neck, 
abdominal, pelvic, and neuropathic pain [20], among others. Depression and pain 
share neurobiological pathways and neurotransmitters: depression is the result of 
an imbalance or functional deficiency of monoamines such as dopamine, serotonin, 
and norepinephrine. When these neurotransmitters decrease, the modulating effect 
of the GPA (periaqueductal gray) system is lost, which is the anatomical key to 
modulating pain or nociceptive pathway. When this happens, the lower body signals 
are amplified, and more emotions and attention are focused on it, that is why 
depressed patients report feeling pain in various body parts [27].
Dementia is a syndrome of damage or cognitive impairment that affects the 
lifestyle of people. The incidence of this disorder is high; it is estimated that in the 
world a new case of dementia occurs every 4 s. The most common form is associated 
with Alzheimer’s disease in the elderly [28]. There are proposals on the mechanism 
that takes place to develop dementia, such as alterations in the immune system, 
cholesterol metabolism, endocytosis of neurotransmitters in the central nervous 
system, alterations in the vascular system, and frontotemporal lobar degeneration 
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(FTLD) [29]. Almost half of older people with dementia suffer any type of pain. 
Some of the most important changes related to dementia may arise cognitive domain 
of pain, such as alterations in semantic and episodic memory, executive function, 
and anticipation of it. Some studies have shown that dementia reduces the experi-
ence of pain, although what is suggested is that patients cannot recognize or remem-
ber this symptom [30]. Recognition of pain in people with this condition should be 
considered because it changes the quality of life of patients. If they cannot recognize 
the pain, or cannot to verbalize it, they will not be evaluated or treated properly [31].
Schizophrenia is another heterogeneous psychiatric disorder with a broad 
spectrum of clinical and biological manifestations. Patients with this disorder show 
structural changes in the brain, as well as the decreased volume of the hippocampus 
and cortex, and the lengthening of ventricular spaces. There are also changes in the 
organization and size of neurons and other brain cells. It has been shown that there 
are alterations in the dopaminergic and glutamatergic neurotransmission in the 
limbic system. On the other hand, peripheral molecular markers have been associated 
with developing this disease, such as IL-1β, IL-6, and TNF-α, which are known as 
pro-inflammatory cytokines [32]. With the release of these cytokines, an activation 
state of low-grade inflammation is reached, which worsens the prognosis of patients 
in relation to positive and negative psychotic symptoms, cognitive impairment, and 
loss of brain volume. In addition, an over activation of the HPA axis is observed, with 
a sustained release of cortisol [33]. One of the classic symptoms of schizophrenia, but 
which is not given much attention, is a pain without experimental provocation, includ-
ing the percentage of people with this disease indicating which pain is not high. This 
may be due to reduced pain sensitivity in these patients produced by neuroanatomical 
alterations in the medial prefrontal and temporal areas of the brain since it is known 
that motivational-affective pain processing requires this intact neural circuit [34].
In summary, pain can modify the course of psychopathologies, as well as these 
conditions may alter the perception or memory pain (how it is recalled). Knowing 
how the neurobiological substrates in both (psychiatric disorders and pain) con-
verge, help a better way to treat pathologies, and provide an opening to new forms 
and strategies to face or prevent them.
5. Conventional pain management
The pharmacological treatment of pain includes a wide range of medications, 
which mainly include nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, 
antidepressants, and anticonvulsants. Classic NSAIDs were developed in the early 
1900s, being the prototype the acetylsalicylic acid (aspirin), which possess anti-
pyretic, anti-inflammatory, and analgesic actions. Subsequently, other molecules 
with similar activity were incorporated as paracetamol (acetaminophen), phen-
ylbutazone, indomethacin, fenamates, naproxen, and ibuprofen [35, 36]. These 
drugs are prescribed for the management of inflammatory pain, and their analgesic 
effects of the latter are partly explained by reducing the biosynthesis of prostaglan-
dins mediated by the inhibition of cyclooxygenase (COX), which leads to a reduc-
tion or reversal of peripheral sensitization. However, NSAIDs also modulate pain 
intensity by suppressing prostanoid biosynthesis in the central nervous system, 
thus affecting central sensitization [37].
The production of prostaglandins depends on the release of arachidonic acid, 
which in turn is released as a result of the action of phospholipase A2 on cell mem-
brane phospholipids. The cyclooxygenase and lipoxygenase pathways represent the 
main routes for the oxidative metabolism of arachidonic acid. The catabolism of 
eicosanoic acid by cyclooxygenase produces cyclic prostaglandins. The peroxidation 
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catalyzed by lipoxygenase gives rise to straight-chain hydroperoxyeicosatetraenoic 
acids (HPETEs), which may then be converted into hydroxyeicosatetraenoic acids 
(HETEs) and leukotrienes (LTs). Prostanoids (prostaglandins and thromboxane) 
do not activate nociceptors directly but sensitize them to both mechanical stimuli 
and other chemical mediators of nociception, such as bradykinin and histamine. 
However, stable E-series prostaglandins are clearly involved in the hyperalgesia 
observed in acute inflammation. Prostaglandin E2 (PGE2) is the predominant 
eicosanoid in many inflammatory conditions, acting synergistically with other 
mediators to sensitize receptors in afferent nerve endings to produce inflammatory 
pain. All NSAIDs inhibit the synthesis of prostaglandins at one or more points in the 
endoperoxide biosynthesis pathway. This unique property is a general characteristic 
and is believed to be the basis of their analgesic action [38].
Combinations of analgesics (Ketoprofen and Nefopam) with different mecha-
nisms of action have been evaluated in distinct animal models of pain (acetic 
acid-induced writhing, formalin-induced licking in mice, induction of carrageenan 
unilateral hind-paw inflammation, and, induction of unilateral hind-paw incision 
in rat). Ketoprofen is an NSAID, which exhibits efficient antinociception in humans 
and animal models, particularly in inflammatory pain; its main mechanisms of 
action involve the inhibition of COX and lipoxygenase decreasing the production 
of prostaglandins and leukotrienes, respectively. On the other hand, Nefopam is an 
antinociceptive compound with both supraspinal and spinal sites of action, and its 
mechanism of action involves the inhibition of monoamine reuptake in the central 
nervous system; it increases the inhibiting tone of serotonergic and norepineph-
rine descending pathways by inhibiting the synaptosomal uptake of dopamine, 
norepinephrine, and serotonin. This study concluded that the co-administration is 
synergistic and should allow either to increase their analgesic efficacy or to reduce 
their side effects [39].
In a recent study of preclinical research, it was observed that pretreatment of 
male CF-1 mice with either clomipramine [1.0 mg/kg i.p. or 0.8 mg/kg intrathe-
cal (i.t.)] or risperidone (0.01 mg/kg either i.p., as intrathecal) increased the 
antinociceptive potency of several NSAIDs, expressed by a decrease in the values 
of antinociceptive ED50 in a chemical model of inflammatory acute visceral pain, 
the abdominal acetic acid induced a writhing test in mouse. For the study, dose-
response curves, i.p. or i.t., were performed to determine the ED50 of each of 
the NSAIDs: Ketoprofen (3, 10, 30, and 100 mg/kg, i.p. or 0.1, 0.3, 1, and 3 mg/
kg, i.t.), Piroxicam (1, 3, 10, 30, and 100 mg/kg, i.p. or 0.1, 0.3, 1, and 3 mg/
kg, i.t.), Nimesulide (1, 3, 10, and 30 mg/kg, i.p. or 0.03, 0.1, 0.3, and 1 mg/kg, 
i.t.), Parecoxib (0.3, 1, 3, and 10 mg/kg. i.p. or 0.1, 0.3, 1, and 3 mg/kg. i.t.), or 
Paracetamol (10, 30, 100, and 200 mg/kg, i.p. or 1, 3, 10, and 30 mg/kg, i.t.) [40].
Opioids are the main group of pharmacological therapies for pain. Useful guide-
lines for their administration have been developed for several clinical situations, 
including treatment of acute pain, trauma, cancer, nonmalignant chronic pain, and 
pain in children. In the case of cancer pain, adherence to standardized protocols can 
improve pain management significantly [41, 42]. Opioids should be prescribed con-
comitantly with other analgesics such as NSAIDs or paracetamol since they show a 
synergistic effect, and by reducing the dose of both, the possible adverse effects are 
reduced. This “opioid-sparing” strategy is the backbone of the “analgesic ladder” 
for pain management proposed by the WHO. If the intensity of pain is increased, 
weak-to-strong opioid medication can be adjusted, in which case they should be 
prescribed for continued dose or infusion, so that plasma levels remain stable and 
unnecessary suffering is avoided [4].
Gabapentinoids are recommended as first-line agents for neuropathic pain 
[43, 44]. Two examples of these substances are Pregabalin and Gabapentin 
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not only used as an anticonvulsant but also prescribed to the management of 
postherpetic neuralgia without effects in painful sciatica [45]. Carbamazepine, 
Lamotrigine, and Oxcarbazepine are the first choice for the medical treatment of 
trigeminal neuralgia [46, 47]. They act as a dependent sodium channel blocker. 
Because of the unexpected drug interactions caused by a reduction in the activity 
of various hepatic cytochrome P450 enzymes that affect drug metabolism, carba-
mazepine is not recommended to treat any other types of neuropathic pain [44].
The first-line drugs to neuropathic pain include tricyclic antidepressants (TCAs) 
and selective serotonin-norepinephrine reuptake inhibitors (SSNRI). TCAs are 
recommended based on efficacy, safety, toxic effects, and cost [44]; they are effica-
cious for several types of neuropathic pain including diabetic peripheral neuropathy 
(DPN), nerve injury pain, PHN, and central post-stroke pain. The analgesic effects of 
TCAs are related to inhibiting the reuptake of noradrenaline and serotonin from pre-
synaptic terminals [48]. Amitriptyline is the TCAs most prescribed in many circum-
stances where neuropathic pain is presented as central pain, DPN, and PHN [44]. 
SSNRIs, such as Venlafaxine and Duloxetine, are an effective drug in the treatment of 
neuropathic pain [49, 50]. They are mainly studied on painful polyneuropathy.
In recent years, connexins (Cxs) have been studied as targets for the develop-
ment of new analgesic drugs. Connexins are a family of proteins with 20 subtypes 
and function as channels, junctions between cells, and hemichannels that sample 
the extracellular space and release substances such as neurotransmitters. One of 
the Cxs, Cx43, is expressed in astrocytes at the level of the central and peripheral 
nervous system. This has been studied in animal models and related to the genesis 
and maintenance of chronic pain, so it could be a promising therapeutic target for 
future treatments that act as Cx43-gap junction blockers, at the level of the trigemi-
nal ganglion and the sciatic nerve [51].
6. Side effects and toxicity in pain pharmacotherapy
NSAIDs can promote various degrees of toxicity related to their pharma-
cokinetic and pharmacodynamic properties [11]. Its long-term use is a leading 
cause of morbidity especially in patients with risk factors, such as peptic ulcer 
and myocardial infarction, among others. The administration of these drugs or 
paracetamol frequently produces adverse effects such as gastrointestinal bleeding, 
hypertension, risk of infarction, hepatotoxicity, and renal failure [52–55]. Up to 
25% of patients treated with NSAIDs have sodium retention, resulting in weight 
gain and developing peripheral edema. Likewise, hypersensitivity phenomena may 
occur, such as fever, rash, and eosinophilia [56]. About 15% of patients treated 
with NSAID presented significant elevations of liver-damaging enzymes, primarily 
alanine transaminase (ALT) and aspartate transaminase (AST), especially when 
administering Diclofenac and Sulindac [11]. Also, prostaglandins have an impor-
tant role in female reproduction processes; it has been demonstrated by testing in 
mice the inhibition of COX-2 activity given by NSAID results in ovulation failure, 
fertilization, and implantation. Studies in animal models have also shown that these 
treatments modify the correct healing and union of fractures. Studies have not been 
conclusive since recovery depends on the type of wound, duration, and dose of the 
drug [57]. An increased risk of myocardial infarction has also been found in COX-2 
inhibitors, presenting effects on blood pressure and nitric oxide production. Such 
is the case that ibuprofen interferes with the platelet effect and increases up to 35% 
risk of having myocardial infarction [58, 59].
On the other hand, the side effects of opioids include dry mouth [41], constipa-
tion, respiratory depression, nausea and urinary retention, motor impairment [60], 
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as well as addiction, tolerance, and paradoxically hyperalgesia [42, 53]. Depression 
and respiratory disorders are a common and known treatment effect, caused by 
the activation of opioid receptors (mu, kappa, and delta) expressed in the brain-
stem respiratory centers [61]. In addition, opioids affect dopaminergic and adren-
ergic systems that can mediate reward and addiction pathways [62, 63]. Preclinical 
and clinical research has concluded that chronic opioid use alters endocrine 
functioning and food intake and increases body weight, which in turn is related to 
constipation and nausea [53, 64]. Excessive exposure to opioids may develop toler-
ance, through activation mediated by the NMDA receptor (N-methyl-D-aspartate) 
and an increase in pain sensitivity that manifests as hyperalgesia and/or allodynia 
in patients. NMDA receptor antagonists relieve tolerance and dependence on 
morphine [62, 63].
Due to their anticholinergic effect, TCAs can increase the risk of cardiovascular 
events and reduce secretions, so they are contraindicated in patients with kidney 
disease, urinary retention, glaucoma, or serious cardiovascular diseases. On the 
other hand, SSNIRs can cause hives, itching or rash, headache, restlessness, nausea, 
and dry mouth; they have also been associated with an increased risk of suicide in 
people suffering from major depression [44].
In synthesis, conventional therapies to treat different types of pain are not 
exempt from serious side effects and toxicity, particularly opioids, whose effects 
on the central and peripheral nervous system promote life-threatening respira-
tory depression, addiction, pruritus, nausea, and constipation [2]. This situation 
represents a serious health problem that has been increasing due to the practice of 
prescribing opioids for pain management [65].
7. Medicinal plants as potential treatment of pain: preclinical research
7.1 Animal models of pain
Animal experimentation has been a very important tool in elucidating the 
mechanism that underlies certain diseases [66] and contributes to the improve-
ment of diagnostic and prophylactic procedures as well as the understanding of 
the etiology and pathogenicity of different diseases [67]. These animal models 
offer the advantage of their standardization, genetic, and environmental back-
ground [68].
Animal pain perception shows similarities to human pain; thus, animal models 
mimic the persistent pain found in the clinic, and thus, animal studies give an idea 
of certain aspects of human pain conditions and lead to better pain management 
in patients [69]. Most nociceptive assays involve a noxious stimulus that can be 
thermal, chemical, mechanical, or electrical to specific parts of the body, resulting 
in simple noxious behaviors that can be easily qualified [70]. On the other hand, 
neuropathic pain models involve an injury or disease that affects the somatosensory 
system and include spontaneous pain, painful hyperalgesia, or allodynia [71].
Although we define pain as a homogeneous sensory entity, it is important to 
emphasize the etiological distinction of pain, as it is one of the most important and 
studied to define the neurobiological mechanisms responsible and provide an idea 
of how different types of pain are generated [72].
Research into new treatments for pain relief and their mechanisms has justified 
the use of different animal models developed to better understand the progress of 
specific disease issues. However, one of the most important needs when implement-
ing an experimental model is that it reflects the necessary clinical conditions, from 
inflammatory pain to chronic low back pain. Therefore, over time several animal 
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models have been standardized that can evaluate different characteristics of pain. 
The Table 3 shows the most important experimental pain models [1, 73–77].
7.2 Effects of medicinal plants on animal models of pain
Most often, pain is treated with allopathic or conventional pharmacological 
medicine, a vast pain conditions are complex to treat because of financial strains or 
adverse side effects. However, complementary and alternative medicine might be a 
novel solution because their great repertoire of techniques includes nonpharmaco-
logical remedies (massage, acupuncture, yoga, etc.) and the use of herbal medicine 
[5] to reduce opioid misuse, diminish avoidable costs, and improve health outcomes 
[78]. Therefore, herbal medicine is an important element of health systems in many 
developing and industrialized countries [79].
For the World Health Organization (WHO), “herbal medicines include herbs, 
herbal material, herbal preparations, and finished herbal products, which contain 
as active ingredients parts of plants, or other plant materials, or combinations of 
those elements” [80]. The popular use of medicinal plants in health care in many 
tropical and subtropical countries is widely described because of their enormous 
plant diversity. The consumption of medicinal plants has been important not only 
for the treatment of pain but also for treating diseases and metabolic disorders 
[81]. Therefore, the urge to gather more ethnobotanical and preclinical evidence to 
support the traditional uses of plants.
Nociceptive pain models
Model Type of stimulus or injury Natural metabolites evaluated
Hot plate test
Hargreaves test
Thermal Organic compounds with possible 
antiharmful activity
Substances with antiharmful properties, 
Flavonoids, Triterpenes, Carbohydrates, 
Phenols, Terpenoids, Coumarins, and 
Saponins, among others
Tail flick test Thermal
Tail immersion test Thermal
Paw/tail pressure test and 
Von Frey
Randall-Selitto
Mechanical
Electric stimulation of 
the tail
Electric
Abdominal constriction 
test
Chemical
Formalin test Chemical
Inflammatory pain models
Model name Kind of stimulus or injury Natural metabolites evaluated
Capsaicin Injection into skin, muscles, 
or joints
Phytochemical compounds with possible 
anti-inflammatory activity
Polyphenols, Flavonoids, Quercetin, 
Phenolic compounds, Carotenoids, 
Quercetin, Catechin, Kaempferol, 
Epicatechins, Lupeol, Triterpenes, 
Phytosterols, Sterols, Lignans, 
Anthocyanins, and Alkaloids, among 
others.
Carrageenan Injection into the leg, muscle, 
and joint
Complete Freund 
Adjuvant (CFA)
Injection into the tail, leg, 
muscle, and joints
Kaolin/carrageenan Injection into knee or ankle 
joint
Zymosan Injection into knee or ankle 
joint
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Several biological effects of extracts and purified compounds from herbal spe-
cies have been tested in vivo and in vitro models. Extracts have shown antimicrobial, 
antiviral, and antimutagenic activity; cytotoxic activity for cancer cell lines and 
antinociceptive, anti-inflammatory activity; and antiatherogenic, antioxidant, and 
biocide for various food pests [82]. Based on the biological models of neuropathic 
pain, we can mention neuropathic pain induced by paclitaxel, chronic constric-
tion injury, alcoholic neuropathy, streptozotocin-induced diabetic, partial sciatic 
nerve ligation, and model of sodium monoiodoacetate. Among the main secondary 
metabolites that have diminished pain are alkaloids, carotenes, flavonoids, phenols, 
and terpenes, among others [83]. Some species with analgesic profile and their 
metabolites are shown in Table 4.
The Pterodon pubescens (Benth) has been described as an analgesic. 
Phytochemistry studies have reported the presence of a high concentration of 
terpenes. The analgesic properties of Pterodon pubescens are attributed to these 
compounds [103]. An experimental study conducted in mice using the model of 
Neuropathic pain models
Model name Type of stimulus or injury Natural metabolites evaluated
Axotomy Complete sciatic nerve 
transection
Opioids and tricyclic antidepressants, 
calcium antagonist (Verapamil, 
Nifedipine), sodium channel blockers 
(Lidocaine, Mexiletine, Tocainide), NMDA 
receptor antagonist (Dextromethorphan, 
Ketamine, Memantine), calcium N-channel 
blockers (Ziconotide), Antiepileptics 
(Gabapentin, Topiramate, Lamotrigine, 
Felbamate)
Chronic constriction 
injury
Four loose ligatures around 
sciatic nerve
Partial sciatic nerve 
ligation (Seltzer Model)
Tight ligation of one-third to 
half of the sciatic nerve
Spared nerve injury Axotomy of tibial and 
common peroneal nerves
Tibial and sural nerve 
transection
Axotomy of tibial and sural 
nerves
Sciatic cryoneurolysis Freezing of the sciatic nerve
Sciatic inflammatory 
neuritis
Injection of zymosan, HMG, 
TNF-α around the sciatic 
nerve
Laser-induced sciatic 
nerve injury
Radiation mediated reduction 
in blood supply to the sciatic 
nerve
Excitotoxic spinal cord 
injury
Intraspinal injections of 
excitatory amino acids
Spinal hemisection Laminectomy of T11–T12 
segments
Diabetes-induced 
neuropathy
Persistent hyperglycemia-
induced changes in the nerves
Trigeminal neuralgia Compression of trigeminal 
ganglion chronic constriction 
injury to the infraorbital 
nerve
Orofacial pain Injection of formalin, 
carrageenan into 
temporomandibular joints 
and maxilla
Table 3. 
Principal animal models of pain.
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neuropathic pain induced by partial sciatic nerve ligation showed that the admin-
istration of ethanolic extract of Pterodon pubescens, at an oral dose of 300 mg/kg, 
was effective in exerting antinociceptive effects, revealing a possible mechanism 
of action associated with the significant bite suppression induced by kainate, 
glutamate, NMDA, and trans-ACPD. Also, the plant extract decreased the concen-
tration of proinflammatory cytokines like TNF-α and IL-1β and the inhibition of 
channels of capsaicin (TRPV1) and cinnamaldehyde (TRPA1), respectively, without 
pharmacological tolerance. The most abundant metabolites extracted from these 
plants were sesquiterpenes and diterpenes, which suggest that these compounds are 
responsible for the therapeutic effect [104]. There is interest in the study of other 
plant species, including Woodfordia fruticosa, Adhatoda vasica, Chenopodium ambro-
sioides, Viburnum cotinifolium, Vitex negundo, Peganum harmala, and Broussonetia 
papyrifera because of the presence of effective alkaloids for pain treatment. The 
crude alkaloid extracts of all selected medicinal herbs were active at an oral dose of 
1250 mg/kg of body weight in mice, where they reduced abdominal contractions 
Group of 
metabolite
Isolated 
metabolite
Plant containing 
the metabolite
Pharmacological effects References
Alkaloid Morphine
Codeine
Thebaine
Papaverine
Papaver somniferum
Woodfordia fruticosa
Peganum harmala
Antinociceptive, 
anti-inflammatory, and 
antineuropathic
[84–86]
Flavonoid Quercetin
Rutin
Kaempferol
Luteolin
Myricetin
Apigenin
Azadirachta indica
Aloe vera
Allium cepa
Calamus scipionum
Camellia sinensis
Carica papaya
Psidium guajava
Peripheral neuropathy, 
anti-inflammatory, and 
antinociceptive
[87–90]
Carotene β-carotene
Lycopene
Capsicum annuum
Ginkgo biloba
Solanum 
lycopersicum
Daucus carota
Acute or chronic pain: i.e. 
inhibiting the release of 
TNF-α and stimulating 
IL-10 production
[91, 92]
Phenol Catechol
Resorcinol
Hydroquinone
Phloroglucinol
Vanillic acid
Gallic acid
Siegesbeckia 
orientalis
Ageratum conyzoides
Mikania cordifolia
Moringa oleifera
Plantago altissima
Plantago lanceolata
Antinociceptive and 
anti-inflammatory
[93–96]
Terpene Thymoquinone
Linalool
Menthol
Eugenol
Fenchone
Citronella
Hyptis pectinata
Hyptis fruticosa
Erythrina velutina
Aniba rosaeodora
Mentha piperita
Daphne aurantiaca
Antinociceptive and 
anti-inflammatory
[97, 98]
Saponin Digitonin
Sarsasapogenin
Dioscin
Asparagus 
racemosus
Tribulus terrestris
Acute or chronic pain; 
antinociceptive, anti-
inflammatory, and 
neuropathic
[99, 100]
Statins Atorvastatin
Lovastatin
Trianthema 
portulacastrum
Anti-nociceptive and 
anti-inflammatory
[101, 102]
Table 4. 
Secondary metabolites with analgesic potential.
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caused by acetic acid and increased the latency time between the licks of the legs 
in both phases of pain (neuropathic and inflammatory) produced with formalin. 
In addition, the alkaloid-specific antinociceptive response was significantly in the 
naloxone model [86].
Another group of plants of pharmacological interest is the genus Polygala and 
the Lamiaceae family that have been widely used in pain therapy [105]. Polygala 
molluginifolia has shown important antinociceptive effects in mice. An experi-
mental study showed that the hydroalcoholic extract of this plant, administered 
at a dose of 1000 mg/kg, exerted analgesic effects in a model of mechanical and 
thermal hyperalgesia to postoperative pain in mice. The mechanism of action of the 
experiment revealed that the effect of the natural product might be associated with 
a modulation of the TRPV1 and TRPA1 channels involved in nociceptive behavior 
and was demonstrated that Polygala molluginifolia has an antinociceptive potential 
without collateral effects like locomotor dysfunctions or sedation [106].
The phytochemistry of the species of the genus Agastache (Family Lamiaceae) 
is generally similar among them and consists of two classes of major metabolites: 
phenylpropanoids and terpenoids. The essential oils obtained from the family that 
has been identified more than 50% of estragole and volatile compounds such as 
methyl eugenol, pulegone, menthone, isomenthone, and spathulenol. The main 
nonvolatile metabolites are phenolic compounds, such as those derived from caffeic 
acid, especially rosmarinic acid, as well as several flavones and flavone glycosides 
such as acacetin, tilianin, agastachoside, and agastachin. Lignans, agastenol and 
agastinol, were also isolated, as well as terpenoids include oleanane type (maslinic 
acid, oleanolic acid, and β-amirin), ursane type (ursolic acid, corosolic acid, and 
α-amirin), typical plant sterols, and diterpenes (agastaquinone, agastol, and others) 
[82]. The plants of the Lamiaceae family are widely used as condiments, and some 
popular are oregano, thyme, and rosemary, but aromatic ones such as mint, basil, 
and sage are also part of this family [107].
About 250 species belong to the genus Lippia (Family Verbenaceae) and are dis-
tributed throughout Central and South America, as well as in the African continent. 
They are usually sold for the treatment of different types of pain, including stomach 
pain, abdominal pain, and headache, and are used as sedatives, anxiolytics, and 
anticonvulsants [108]. Lippia alba, L. multiflora, L. gracilis, L. grata, L. origanoides, 
L. graveolens, L. geminata, L. origanoides, and L. adoensis are the species that have 
reports worldwide on their effect on system disorders such as central nervous, pain, 
and inflammation [109].
Lippia origanoides commonly known in Mexico as “oregano” and Lippia multiflora 
also known in Africa are popularly used to control fever treat gastrointestinal disor-
ders, enteritis, and cough. Composite leaves and flowers such as p-cymene, thymol, 
and carvacrol [110] were isolated from which the analgesic and antipyretic proper-
ties have been attributed, evaluated in mice and rats using carrageenan-induced 
hind paw as model of acute inflammation, and the analgesic effects were assayed by 
thermal, mechanical, and chemical models of antinociception, and this was cor-
related with an increase in glutathione and a decrease in nitric oxide and malondial-
dehyde, demonstrating a decrease in the levels of nitric acid and malonyl aldehyde 
process mediators such as inflammatory and pain [110]. A monoterpene called 
carvacrol has been isolated from oregano, which has shown antinociceptive effects. 
This metabolite was studied in an orofacial pain model and demonstrated that 
when administered at a dose of 20 mg/kg, it exerts antinociceptive effects in mice; 
however, this effect is punctuated more effectively if the metabolite is administered 
concomitantly with β-cyclodextrin [111]. Carvacrol/β-cyclodextrin has also been 
studied in cancer-induced pain models. Administered at a dose of 50 mg/kg, they 
exert antinociceptive effects in rodents that have tumors implanted in their hind 
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paw [112]. An interesting fact about carvacrol is that its analgesic effects decrease 
when administered alone and increase when administered with cyclodextrin. On the 
other hand, carvacrol and p-cymene have an analgesic effect related to the decrease 
of pain mediators such as proinflammatory cytokines (IL-1, TNF, IL-4, TGF and 
IL-17) and anti-inflammatory (IL-10) [113, 114].
Hexane, ethyl acetate, and ethanol extracts from Agastache mexicana subsp. 
xolocotziana showed an antinociceptive effect in rats and mice. The ethyl acetate 
extract (containing significant amounts of ursolic acid) was the most active in the 
formalin-induced pain model, mainly in the inflammatory (second) phase; hexanic 
extract (present pulegonic and oleanolic acid) decreased thermal pain. The metha-
nolic extract (rich in flavonoids such as acacetin and tilianin) was more active in the 
formalin model and in the acetic acid contortion model [82].
Rosemary plant has been assessed in Diabetes Mellitus cases of pain models. A 
study in rats showed that rosemary extract administration at 100, 150, and 200 mg/kg 
doses decreased hyperalgesia through the suppression of caspase-3. In this study, 
the neuroprotective effect of rosemary was also demonstrated, so that the authors 
suggested that the mechanisms of action might be involved in the inhibition of 
neuronal apoptosis [115].
The Mentha spicata plant, popularly known as garden mint, showed significant 
analgesic effects at the preclinical level. Phytochemical studies have revealed 
the presence of metabolites such as carvone, limonene, and menthol. Basil plant 
(Ocimum basilicum) has also shown analgesic effects combined with β-cyclodextrin. 
Studies have been conducted from basil essential oils, which are rich in monoter-
penes. A study conducted in animal models of fibromyalgia showed that essential 
oils administered orally, at doses of 25, 50, and 100 mg/kg, significantly reduced 
mechanical hyperalgesia in mice [116, 117].
In addition to the plants described above, many others have presented signifi-
cant effects in pain therapy in preclinical models associated with certain metabolites 
(see Table 5). Nevertheless, further molecular studies on secondary metabolites 
are needed, which allow to accurately indicate the mechanisms of action, and 
the effects can be compared with those analgesics already in the market. Further 
research is required to achieve analgesic effects at the lowest possible doses to signif-
icantly reduce the number of adverse reactions in organisms, particularly because 
the use of natural resources has become increasingly active in recent years because 
of the belief that natural products lack side effects [118]. Nevertheless, herbal 
therapy is risky because there are effects caused by plant metabolites that may vary 
depending on several external factors such as pollution, conservation processes, 
and the presence of pesticides, among others yet to be evaluated. As a result, the use 
of botanical medicine requires rigorous standardization processes that guarantee 
safety in its use [119]. The variety of soils and climates in such countries facilitates 
the growth of a wide range of plants. Nevertheless, the native people use plants 
empirically, which had led to the lack of standards in their use in terms of effective-
ness, safety, and quality [120]. This idea has triggered the worldwide development 
of drugs used in plants, which lead to the phytomedicine trade worldwide [118].
Phytomedicine differs from synthetized chemical-pharmaceutical drugs in 
their components. A chemical-pharmaceutical drug is synthesized and designed 
in such a way we can have a pure compound or at least a small mixture of chemical 
molecules. Conversely, phytomedicine is plant extracts that contain numerous and 
not well-known compounds. As a result, the source of the plant material requires 
quality production and standardization of the extracts to guarantee the identi-
fication and purification of the compounds that target pain [121]. The increased 
popularity of herbal medicine worldwide had led to numerous reports that support 
its regulation. In some countries, regulations have been legally established in order 
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Plant Potential active 
metabolite involved
Animal model used Effects on pain References
Cannabis 
sativa
∆9-Tetrahydro-
cannabinol
Cannabidiol
Male and female mice  
in a chronic neuropathic  
sciatic nerve injury model
Reduce allodynia, 
hyperalgesia, and 
ultrasonic clicks
[123]
Papaver 
somniferum
Morphine Male and female mice in a 
chronic neuropathic sciatic 
nerve injury model.
Reduce allodynia, 
hyperalgesia, 
and ultrasonic 
clicks but develop 
tolerance after 
1 week
[123]
Urtica 
dioica, 
Urtica 
urens,  
and Urtica 
circularis
Phenolic compounds 
and hydroxy fatty 
acids
Anti-inflammatory in vitro 
COX-1 enzyme; Swiss mouse 
females in the formalin test  
and acetic acid-induced 
abdominal writhing test
Reduce the 
nociceptive 
response
[124, 125]
Verbesina 
persicifolia
Sesquiterpene-
lactones (eudesman, 
cadinane, 
germacrane, and 
elemane)
TPA 
(12-O-tetradecanoylphorbol-
13-acetate)-induced ear  
edema test
Anti-
inflammatory 
activity
[126, 127]
Costus 
pictus, 
Costus 
spicatus
Flavonoids, flavonol 
glycosides, and 
polysaccharides
Male OF-1 mouse in 
formalin, acetic acid-
induced abdominal writhing 
models; hot plate
Antinociceptive 
but not anti-
inflammatory 
effect
[128, 129]
Valeriana 
officinalis
Sesquiterpene and 
iridoids
Orofacial formalin test Reduce the 
nociceptive 
response
[130, 131]
Calotropis 
gigantea 
(L) R. Br.
Flavonoids, 
alkaloids, 
triterpenoids, 
steroids, saponins, 
phenols, and 
glycosides
Hot plate and acetic acid-
induced abdominal writhing 
model
Decrease the 
number of paws 
licking and 
writhing
[132]
Curcuma 
longa L.
Alkaloids, 
flavonoids, saponins, 
and tannins
Curcumin
Demethoxy-
curcumin
Bisdemethoxy-
curcumin
Acetic acid-induced induced 
abdominal writhing model.
Tail flick test; tail immersion 
test
Reduce the 
number of 
writhing.
Increase latency; 
reduce the tail 
withdrawal time
[133–135]
Gastrodia 
elata
4-Hidroxy-
benzaldehyde
4-Hidroxybenzyl 
alcohol
Benzyl alcohol
Vanillin
Vanillic acid
Carrageenan, acetic acid, 
arachidonic acid (AA)-
induced paw edema and 
writhing models.
Cyclooxygenase activity.
Analgesic 
and anti-
inflammatory 
activity
Inhibit the 
activity of  
COX-I/II
[136]
Spilanthes 
acmella, 
Acmella 
oleracea
Alkaloids, 
flavonoids, tannins, 
and carotenoids
N-alkylamides
Spilanthol
Formalin, capsaicin 
and cinnamaldehyde, 
carrageenan-induced paw 
edema models; hot plate and 
tail flick; traumatic sciatic 
nerve injury
Antinociceptive 
and anti-
inflammatory 
effect; increase 
paw withdrawal 
latency 
and reduce 
mechanical 
allodynia
[137, 138]
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to safeguard public health, ensuring quality, efficiency, and safety. For instance, 
the European Union has one of the most complete regulatory systems for the use of 
herbal medicine [122]. Since the combination of both conventional and traditional 
herbal therapy has been poorly explored, it must be careful to avoid serious adverse 
reactions [81].
8. Final comments and conclusion
Pain is unpleasant sensory and emotional experience associated with actual or 
potential tissue damage, being one of the most persistent and disabling manifesta-
tions present in several conditions and diseases mentioned in this chapter, such as 
tissue injuries and bumps, postoperative surgery, cancer, diabetes, mood disorders, 
dementia, and schizophrenia, among others.
In this chapter, it was highlighted that the pain is continually reclassified due 
to its severity and complexity, coupled with the difficulty of describing it, despite 
the fact that there are currently more reliable and valid instruments. This activ-
ity is of great importance to improve the diagnosis and sure adequate therapeutic 
management.
Because pain is a global public health problem, there is a large class of drugs used 
for its treatment, such as opiates, tricyclic antidepressants, and antiepileptic drugs. 
As shown in this review, the prescription of this conventional painkiller depends 
on the type of pain, its duration, origin, and intensity. However, the side effects 
shown by these compounds hinder in many instances, their safe and effective use, 
Plant Potential active 
metabolite involved
Animal model used Effects on pain References
Zingiber 
officinale
Alkaloid, flavonoids, 
and tannins
Hot plate, tail flick test; 
acetic acid-induced pain 
model
Antinociceptive 
effects against 
thermally and 
chemically 
stimulus
[139–141]
Salix alba Alkaloids, tannins, 
polyphenolic salicin 
and glycosides
2-(hydroxymethyl)-
phenyl-B-D-
glucopyranoside
Salicyl-alcohol
Formalin-induced paw 
edema model
Enzymatic action of 
hyaluronidase
Inhibit the paw 
edema
Inhibitory actions 
on biochemical 
pathways of 
arachidonic acid
[85, 142, 143]
Ammi 
majus
Furocoumarins and 
coumarins
Hot plate; formalin, 
carrageenan-hind paw 
edema models
Anti-
inflammatory and 
antinociceptive; 
inhibition of the 
writhing number
[144, 145]
Arnica 
montana
Phenolic 
acids (caffeic, 
chlorogenic), 
flavonoids 
(quercetin, 
palutelin), 
sesquiterpene 
lactones (helenalin, 
dihydrohelenalin)
Hot plate; carrageenan, 
formalin-hind paw 
edema models; cytokines 
determination by ELISA
Inhibition of 
the licking, 
writhing, and 
biting response; 
decrease secretion 
of IL-6 and IL-8 
proinflammatory 
cytokines
[146, 147]
Table 5. 
Active metabolites in pain relief.
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particularly opioids, which could promote life-threatening respiratory depression, 
addiction, pruritus, nausea, and constipation. Therefore, new molecules are being 
sought with specific mechanisms of action that act from the genesis and mainte-
nance of pain at different levels of the nervous system, for example, on the connex-
ins, which would represent an outstanding advance.
On the other hand, in many countries, herbal medicine is used as a complemen-
tary or an alternative strategy to treat pain because it usually lowers costs, is more 
within reach of patients, and has an important cultural root. In this sense, species 
such as Papaver somniferum, Pterodon pubescens, Capsicum annuum, Chenopodium 
ambrosioides, Polygala molluginifolia, Lippia alba, Agastache mexicana, Allium cepa, 
Moringa oleífera, and Hyptis pectinata, among others described in this chapter are 
used due to their analgesics and anti-inflammatory properties. Secondary metabo-
lites such as alkaloids, flavonoids, carotenes, terpenes, and other polyphenolic 
compounds seem to be responsible for the pharmacological effect reported, which 
has been demonstrated from the use of animal models, which show similar percep-
tion to chemical, thermal, electrical, and mechanical stimuli that can induce pain 
than in humans and that constitute one way to approach the study of new molecules 
or herbal extracts with analgesic activity.
Since the combination of both conventional and traditional phytotherapy has 
been poorly explored, this can often lead to harmful effects rather than improv-
ing pain treatment. Meanwhile, most analgesics and herbal products for pain 
treatment are accessible because they do not require a prescription for sale, their 
consumption has been exceeded, and self-medication has led to a major concern 
in several countries. Not regulated herbal therapies can trigger several condi-
tions that may further compromise the patient’s well-being. Currently, research 
on natural products includes the use of organic synthesis for improving natural 
product characteristics. Some research groups synthesize analogs of natural 
compounds and modify its activity to improve the effectiveness of the drug lead. 
Since the use of natural compounds might be risky because of the multiple active 
molecules present in plants, mimicking the targets that produce the desired effect, 
such as diminish pain, it is a useful alternative and avoids the burden of isolating 
molecules from natural resources. In this regard, it is possible to obtain a purified 
compound that can be tested. Molecular biology is a powerful tool to identify 
receptors and proteins, so a perspective in the pharmacological treatment of pain 
could be the development of further research in molecular biology for studying 
the targets of pain and therefore for designing specific molecules that can bind 
directly to pain receptors.
In conclusion, it is crucial that pharmaceutical, neuroscientists, and other 
healthcare professionals must be involved in well-designed preclinical trials to fully 
understand the effects of herbal medicines and phytopharmaceuticals and to study 
the molecular mechanisms and biological targets in which they operate. In terms 
of regulation, it would be important for organisms other than the Food and Drug 
Administration (FDA) in developing countries to establish the mechanisms such as 
to conduct all the preclinical trials before releasing a new drug.
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